Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.
Kolbinger F, Loesche C, Valentin MA, Jiang X, Cheng Y, Jarvis P, Peters T, Calonder C, Bruin G, Polus F, Aigner B, Lee DM, Bodenlenz M, Sinner F, Pieber TR, Patel DD. Kolbinger F, et al. Among authors: jarvis p. J Allergy Clin Immunol. 2017 Mar;139(3):923-932.e8. doi: 10.1016/j.jaci.2016.06.038. Epub 2016 Aug 5. J Allergy Clin Immunol. 2017. PMID: 27502297 Free article.
First-in-human study demonstrating the safety and clinical efficacy of novel anti-IL-17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis.
Kaul M, Jarvis P, Rozenberg I, Kolbinger F, Di Padova F, Calonder C, Espie P, Rondeau JM, Cebe R, Huber T, Mussmann R, Aassi M, Sligh TS. Kaul M, et al. Among authors: jarvis p. J Eur Acad Dermatol Venereol. 2021 May;35(5):1143-1151. doi: 10.1111/jdv.17071. Epub 2021 Jan 5. J Eur Acad Dermatol Venereol. 2021. PMID: 33617042 Free PMC article. Clinical Trial.
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study.
Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I, Jarvis P, Peters T, Roth L, Wieczorek G, Kolbinger F, Jemec GBE. Kimball AB, et al. Among authors: jarvis p. Exp Dermatol. 2022 Oct;31(10):1522-1532. doi: 10.1111/exd.14619. Epub 2022 Aug 19. Exp Dermatol. 2022. PMID: 35638561 Free PMC article. Clinical Trial.
Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
Metz M, Staubach P, Bauer A, Brehler R, Gericke J, Kangas M, Ashton-Chess J, Jarvis P, Georgiou P, Canvin J, Hillenbrand R, Erpenbeck VJ, Maurer M. Metz M, et al. Among authors: jarvis p. Theranostics. 2017 Mar 6;7(5):1266-1276. doi: 10.7150/thno.18304. eCollection 2017. Theranostics. 2017. PMID: 28435464 Free PMC article. Clinical Trial.
A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis.
Radeke HH, Stein J, Van Assche G, Rogler G, Lakatos PL, Muellershausen F, Moulin P, Jarvis P, Colin L, Gergely P, Kruis W. Radeke HH, et al. Among authors: jarvis p. Inflamm Intest Dis. 2020 Nov;5(4):180-190. doi: 10.1159/000509393. Epub 2020 Aug 21. Inflamm Intest Dis. 2020. PMID: 33313070 Free PMC article.
Assessing the predictive value of the rodent neurofunctional assessment for commonly reported adverse events in phase I clinical trials.
Mead AN, Amouzadeh HR, Chapman K, Ewart L, Giarola A, Jackson SJ, Jarvis P, Jordaan P, Redfern W, Traebert M, Valentin JP, Vargas HM. Mead AN, et al. Among authors: jarvis p. Regul Toxicol Pharmacol. 2016 Oct;80:348-57. doi: 10.1016/j.yrtph.2016.05.002. Epub 2016 May 4. Regul Toxicol Pharmacol. 2016. PMID: 27155597 Free article.
The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative.
Ewart L, Aylott M, Deurinck M, Engwall M, Gallacher DJ, Geys H, Jarvis P, Ju H, Leishman D, Leong L, McMahon N, Mead A, Milliken P, Suter W, Teisman A, Van Ammel K, Vargas HM, Wallis R, Valentin JP. Ewart L, et al. Among authors: jarvis p. Toxicol Sci. 2014 Dec;142(2):427-35. doi: 10.1093/toxsci/kfu198. Epub 2014 Sep 21. Toxicol Sci. 2014. PMID: 25246669
302 results